Cargando…

TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer

BACKGROUND: Pancreatic cancer is a highly aggressive malignancy with limited treatment options and a poor prognosis. Trophoblast cell surface antigen 2 (TROP2), a cell surface antigen overexpressed in the tumors of more than half of pancreatic cancer patients, has been identified as a potential targ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Caili, Zhu, Min, Wang, Qian, Cui, Jiajun, Huang, Yuping, Huang, Xiting, Huang, Jing, Gai, Junwei, Li, Guanghui, Qiao, Peng, Zeng, Xian, Ju, Dianwen, Wan, Yakun, Zhang, Xuyao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629078/ https://www.ncbi.nlm.nih.gov/pubmed/37932752 http://dx.doi.org/10.1186/s12951-023-02183-9

Ejemplares similares

Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma
por: Wang, Yichen, et al.
Publicado: (2022)

A potent neutralizing nanobody against SARS‐CoV‐2 with inhaled delivery potential
por: Gai, Junwei, et al.
Publicado: (2021)

Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E
por: Wang, Yichen, et al.
Publicado: (2018)

Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential
por: Ma, Linlin, et al.
Publicado: (2020)

Identification and Characterization of Specific Nanobodies against Trop-2 for Tumor Targeting
por: Hu, Yaozhong, et al.
Publicado: (2022)

Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells
por: Okajima, Daisuke, et al.
Publicado: (2021)

Chimeric antigen receptor T-cell therapy: challenges and opportunities in lung cancer
por: Xu, Caili, et al.
Publicado: (2022)

Cell Membrane-Derived Vesicle: A Novel Vehicle for Cancer Immunotherapy
por: Xu, Caili, et al.
Publicado: (2022)

Editorial: Community series in combinational immunotherapy of cancer: novel targets, mechanisms, and strategies, volume II
por: Xu, Caili, et al.
Publicado: (2023)

Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for the treatment of eosinophilic asthma
por: Ma, Linlin, et al.
Publicado: (2022)

A SIRPαFc Fusion Protein Conjugated With the Collagen-Binding Domain for Targeted Immunotherapy of Non-Small Cell Lung Cancer
por: Liu, Jiayang, et al.
Publicado: (2022)

Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132
por: Cheng, Yezhe, et al.
Publicado: (2022)

Identification and Characterization of a Novel Nanobody Against Human CTGF to Reveal Its Antifibrotic Effect in an in vitro Model of Liver Fibrosis
por: Liu, Rong, et al.
Publicado: (2023)

Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer
por: Liu, Donglin, et al.
Publicado: (2014)

Furan-Conjugated Tripeptides as Potent Antitumor Drugs
por: Ali, Hunain, et al.
Publicado: (2020)

Insights into CD47/SIRPα axis-targeting tumor immunotherapy
por: Zhang, Xuyao, et al.
Publicado: (2018)

Characterization and applications of Nanobodies against human procalcitonin selected from a novel naïve Nanobody phage display library
por: Yan, Junrong, et al.
Publicado: (2015)

Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan
por: Zhao, Ming, et al.
Publicado: (2023)

Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics
por: Bannas, Peter, et al.
Publicado: (2017)

Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers
por: Vranic, Semir, et al.
Publicado: (2022)

A novel nanobody-based HER2-targeting antibody exhibits potent synergistic antitumor efficacy in trastuzumab-resistant cancer cells
por: Liu, Xinlin, et al.
Publicado: (2023)

PEGylated human catalase elicits potent therapeutic effects on H1N1 influenza-induced pneumonia in mice
por: Shi, Xunlong, et al.
Publicado: (2013)

A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease
por: Hu, Xiaozhi, et al.
Publicado: (2022)

Clinicopathologic significance of TROP2 and phospho-TROP2 in gastric cancer
por: Kushiyama, Shuhei, et al.
Publicado: (2021)

The anti-Trop-2 antibody-drug conjugate Sacituzumab Govitecan—effectiveness, pitfalls and promises
por: Guerra, Emanuela, et al.
Publicado: (2022)

Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer
por: Shastry, Mythili, et al.
Publicado: (2022)

Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity
por: Guo, Zong Sheng, et al.
Publicado: (2014)

Nanobody Conjugates for Targeted Cancer Therapy and Imaging
por: Kang, Wei, et al.
Publicado: (2021)

Tyrosinase-Mediated Synthesis of Nanobody–Cell Conjugates
por: Maza, Johnathan C., et al.
Publicado: (2022)

Screening and antitumor effect of an anti-CTLA-4 nanobody
por: Wan, Ruirong, et al.
Publicado: (2018)

Screening, Expression, and Identification of Nanobody against SARS-CoV-2 Spike Protein
por: Su, Qianling, et al.
Publicado: (2022)

A multivalent biparatopic EGFR-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models
por: Fan, Jiansheng, et al.
Publicado: (2021)

Construction of a synthetic phage-displayed Nanobody library with CDR3 regions randomized by trinucleotide cassettes for diagnostic applications
por: Yan, Junrong, et al.
Publicado: (2014)

NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy
por: Miyazaki, Takahiro, et al.
Publicado: (2021)

ICAM1 antibody drug conjugates exert potent antitumor activity in papillary and anaplastic thyroid carcinoma
por: Zhang, Peng, et al.
Publicado: (2023)

The tumor-inhibitory effectiveness of a novel anti-Trop2 Fab conjugate in pancreatic cancer
por: Mao, Yuan, et al.
Publicado: (2016)

Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy
por: Jeong, Jae Ho, et al.
Publicado: (2022)

Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2
por: Dong, Jianbo, et al.
Publicado: (2020)

PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way
por: Yu, Xiaolu, et al.
Publicado: (2022)

Inhibiting TrxR suppresses liver cancer by inducing apoptosis and eliciting potent antitumor immunity
por: Lei, Hong, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_avmtikc5d4lttb8kmp74fj3p26